Lexeo Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Lexeo Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2022 to Q2 2024.
  • Lexeo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$21.2M, a 58% decline year-over-year.
  • Lexeo Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$77.2M, a 21.2% decline year-over-year.
  • Lexeo Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$66.4M, a 12% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$77.2M -$21.2M -$7.8M -58% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$69.4M -$21.7M -$3.02M -16.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-12
Q4 2023 -$66.4M -$14.2M +$384K +2.63% Oct 1, 2023 Dec 31, 2023 10-Q 2024-08-12
Q3 2023 -$66.8M -$20.1M -$3.05M -17.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-12-11
Q2 2023 -$63.7M -$13.4M +$1.7M +11.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$65.4M -$18.7M -$6.16M -49.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-12
Q4 2022 -$59.3M -$14.6M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$17.1M Jul 1, 2022 Sep 30, 2022 10-Q 2023-12-11
Q2 2022 -$15.1M Apr 1, 2022 Jun 30, 2022 10-Q 2023-12-11
Q1 2022 -$12.5M Jan 1, 2022 Mar 31, 2022 10-Q 2023-12-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.